{"nctId":"NCT00041080","briefTitle":"Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","startDateStruct":{"date":"2003-02"},"conditions":["Fallopian Tube Cancer","Primary Peritoneal Cavity Cancer","Recurrent Ovarian Epithelial Cancer","Stage III Ovarian Epithelial Cancer","Stage IV Ovarian Epithelial Cancer"],"count":139,"armGroups":[{"label":"Arm I (thalidomide)","type":"EXPERIMENTAL","interventionNames":["Drug: thalidomide","Other: laboratory biomarker analysis"]},{"label":"Arm II (tamoxifen)","type":"EXPERIMENTAL","interventionNames":["Drug: tamoxifen citrate","Other: laboratory biomarker analysis"]}],"interventions":[{"name":"tamoxifen citrate","otherNames":["Nolvadex","TAM","tamoxifen","TMX"]},{"name":"thalidomide","otherNames":["Kevadon","Synovir","THAL","Thalomid"]},{"name":"laboratory biomarker analysis","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically confirmed stage III or IV ovarian epithelial, fallopian tube, or primary peritoneal cancer that was treated with only 1 prior first-line chemotherapy regimen (platinum/taxane-based)\n* Clinically and radiologically without evidence of measurable and nonmeasurable disease\n\n  * Symptomatic ascites and pleural effusions are considered nonmeasurable disease\n* Must have a biochemical recurrence\n\n  * CA 125 must have been normal prior to or normalized during first-line therapy and then subsequently rose to exceed twice the upper limit of normal\n  * Patients entering study with a CA 125 level less than 100 U/mL must be confirmed a second time within a period of not more than 4 weeks\n  * Patients with a CA 125 level of at least 100 U/mL may be entered without confirmatory measurement\n* Ineligible for a higher priority Gynecologic Oncology Group protocol (if one exists)\n* No history of brain metastases\n* Performance status - GOG 0-1\n* Absolute neutrophil count at least 1,500/mm\\^3\n* Platelet count at least 100,000/mm\\^3\n* Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n* SGOT no greater than 2.5 times ULN\n* Alkaline phosphatase no greater than 2.5 times ULN\n* Creatinine no greater than 1.5 times ULN\n* Creatinine clearance at least 60 mL/min\n* No history of deep venous thrombosis\n* No prior cerebrovascular accident\n* No history of pulmonary embolism\n* No significant infection\n* No grade 2 or greater sensory or motor neuropathy\n* No other malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use at least 1 highly active method and at least 1 additional effective method of contraception for 4 weeks before, during, and for 4 weeks after study participation\n* No prior immunotherapy (e.g., interleukins)\n* No prior biological response modifiers (e.g., monoclonal antibodies)\n* No prior antiangiogenic agents (e.g., carbonic anhydrase inhibitors)\n* At least 3 weeks since prior anticancer chemotherapy and recovered\n* No prior or concurrent tamoxifen or other selective estrogen receptor modulators\n* At least 4 weeks since prior and no concurrent hormones (e.g., estrogen or progesterone)\n* At least 3 weeks since prior anticancer radiotherapy and recovered\n* At least 3 weeks since prior anticancer surgery and recovered\n* Prior second-look surgery without cytoreduction allowed\n* At least 3 weeks since other prior anticancer therapy and recovered\n* No prior interval cytoreduction\n* No concurrent full-dose therapeutic anticoagulation\n* No concurrent antiseizure medications for seizure disorder\n* No concurrent bisphosphonates (e.g., zoledronate)","healthyVolunteers":false,"sex":"FEMALE","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Median Progression-free Survival","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":null},{"groupId":"OG001","value":"4.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":67},"commonTop":["Gastrointestinal","Constitutional","Pain","Peripheral neurologic","Other neurologic"]}}}